Athersys (ATHX) Reports Solid Progress in 2011
Athersys Inc. (Nasdaq: ATHX), a clinical stage biotechnology company focused on the development of its proprietary MultiStem® cell therapy product for the treatment of numerous diseases and conditions, similar to companies like Mesoblast (MSB: ASX) and ThermoGenesis Corp (Nasdaq: KOOL), recently re[...]
Featured Stories
- Pioneers in Regenerative Medicine Reshaping the Landscape of Biotechnology
- Cardium (CXM) Reports New Gene Delivery Methods at Industry Conference
- HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease
- BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
- Preventing the Problem Before it Occurs – Athersys Meets with FDA to Discuss Novel Approach to Suppressing Graft Versus Host Disease in Leukemia and other Cancer Patients
Other News
- World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada
- Fibrocell Science (FCSC) Announces Exclusive Agreement with UCLA
- ISCO Scientists to Present Preclinical Research Results and Industry Conference
- VistaGen CEO Issues Update Letter to Stockholders
- Teva Representative Joins Mesoblast’s Board of Directors
